Neuraxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuraxis, Inc. (NRXS) on October 18, 2024, covering events occurring on October 12, 2024, and October 16, 2024. The company is an emerging growth company incorporated in Delaware and trades on the NYSE American. The filing primarily addresses amendments to existing financing agreements and new unregistered sales of equity securities.
Key Financial Metrics and Capital Structure
The filing details specific capital raising activities rather than operational financial performance metrics such as revenue or net income.
- Flagstaff International Amendment: The total investment commitment under the amended Securities Purchase Agreement (SPA) was reduced from $5 million to $1.8 million.
- Cash Received: As of the filing date, the Company has received $800,000 from Flagstaff International.
- Shares Issued: 336,132 shares of Series B Convertible Preferred Stock have been issued to Flagstaff International to date.
- New Investor SPAs: On October 16, 2024, the Company entered into agreements to sell 60,924 shares of Series B Preferred Stock for an aggregate price of approximately $145,000.
- Stock Valuation: The Series B Preferred Stock has a stated value of $2.38 per share.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity positions outside of the specific transaction amounts noted above.
Material Changes and Transaction Details
The most significant material change is the restructuring of the financing agreement with Flagstaff International, LLC.
- Reduction in Commitment: The Fourth Amendment to the Flagstaff SPA reduced the aggregate purchase price obligation from $5 million to $1.8 million.
- Payment Schedule: Under the new terms, $800,000 has already been paid. The remaining $1 million is scheduled in two installments: $500,000 due before November 27, 2024, and $500,000 due before December 31, 2024.
- Termination Clauses: The agreement includes specific termination triggers, including failure to make payments within 9 calendar days of the due date or uncured breaches by either party by January 9, 2025.
- New Equity Issuance: The Company secured additional capital from several new investors for approximately $145,000, with the right to receive dividends and liquidation preferences expiring on June 30, 2025.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the executed agreements. Key risks and contingencies identified include:
- Liquidity Risk: The Company's ability to receive the remaining $1 million from Flagstaff International is contingent on the investor meeting the November and December 2024 payment deadlines.
- Default Risk: The Flagstaff SPA may be terminated if Flagstaff International fails to make payments within 9 days of the due date or if the Company breaches obligations that are not cured by January 9, 2025.
- Registration Obligations: The Company is required to file a resale registration statement with the SEC within 30 days of the October 16, 2024 agreements and use best efforts to have it declared effective.
Investor Verification Checklist
- Verify the receipt of the $500,000 payment due from Flagstaff International by November 27, 2024.
- Confirm the filing and effectiveness status of the resale registration statement required for the October 16, 2024 investors.
- Monitor the total outstanding Series B Convertible Preferred Stock to assess potential dilution upon conversion to common stock.
- Review the full text of the Fourth Amendment (Exhibit 10.1) for any covenants or conditions precedent not summarized in the 8-K.